Development of radioisotope-labeled peptides of decreased renal accumulation for cancer therapy

近来，使用放射性同位素（RI）标记的肽的癌症治疗作为放射疗法之一受到关注。但是，由于它们在肾脏中的高放射性蓄积，其临床应用困难。另一方面，研究表明，通过向肽部分引入阴离子电荷可以减少肾蓄积。因此，在本研究中，我的目的是开发RI标记的肽，降低肾放射性，并通过引入阴离子电荷保持对癌细胞的亲和力。结果，我发现了一种新的RI标记肽，与未修饰的RI标记肽相比，对癌细胞具有相同的亲和力。

Recently, cancer treatment using radioisotope(RI)-labeled peptides have received attention as one of radiation therapies. But, their clinical application is difficult because of their high accumulation of radioactivity in kidney. On the other hand, it was revealed that the renal accumulation can be reduced by introducing anion charge to peptide moiety. In this study, therefore, I aimed to develop RI-labeled peptides of reduced renal radioactivity with maintaining the affinity for cancer cells by introduction of anion charge. As a result, I found a new RI-labeled peptide having equivalent affinity for cancer cells compared with non-modified RI-labeled peptides.